A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non-small-cell lung cancer

Feng Ming Spring Kong, Kirk A. Frey, Leslie E. Quint, Randall K. Ten Haken, James A. Hayman, Marc Kessler, Indrin J. Chetty, Daniel Normolle, Avraham Eisbruch, Theodore S. Lawrence

Research output: Contribution to journalArticle

125 Citations (Scopus)

Abstract

Purpose: To study whether changes of [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) during treatment correlate with post-treatment responses in tumor and normal lung in patients with non-small-cell lung cancer (NSCLC). Patients and Methods: Patients with stage I to III NSCLC requiring a definitive dose of fractionated radiation therapy (RT) were eligible. FDG-PET/computed tomography scans were acquired before, during, and after RT. Tumor and lung metabolic responses were assessed qualitatively by physicians and quantitatively by normalized peak FDG activity (the ratio of the maximum FDG activity divided by the mean of the aortic arch background). Results: The study reached the goal of recruiting 15 patients between February 2004 and August 2005. Of these, 11 patients had partial metabolic response, two patients had complete metabolic response, and two patients had stable disease at approximately 45 Gy during RT. The mean peak tumor FDG activity was 5.2 (95% CI, 4.0 to 6.4), 2.5 (95% CI, 2.0 to 3.0), and 1.7 (95% CI, 1.3 to 2.0) on pre-, during, and post-RT scans, respectively. None of the patients had appreciable changes in the lung during RT. The peak FDG activity of the lung was 0.47 (95% CI, 0.36 to 0.59), 0.52 (95% CI, 0.40 to 0.64), and 1.29 (95% CI, 0.82 to 1.76), on pre-, during-, and post-RT scans, respectively. The qualitative response during RT correlated with the overall response post-RT (P = .03); the peak tumor FDG activity during RT correlated with those 3 months post-RT (R2 = 0.7; P < .001). Conclusion: This pilot study suggests a significant correlation in tumor metabolic response and no association in lung FDG activity between during RT scans and 3 months post-RT scans in patients with NSCLC. Additional study with a large number of patients is needed to validate these findings.

Original languageEnglish (US)
Pages (from-to)3116-3123
Number of pages8
JournalJournal of Clinical Oncology
Volume25
Issue number21
DOIs
StatePublished - Jul 20 2007

Fingerprint

Fluorodeoxyglucose F18
Non-Small Cell Lung Carcinoma
Positron-Emission Tomography
Radiotherapy
Lung
Neoplasms
Radiation Dosage
Thoracic Aorta
Physicians

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non-small-cell lung cancer. / Kong, Feng Ming Spring; Frey, Kirk A.; Quint, Leslie E.; Ten Haken, Randall K.; Hayman, James A.; Kessler, Marc; Chetty, Indrin J.; Normolle, Daniel; Eisbruch, Avraham; Lawrence, Theodore S.

In: Journal of Clinical Oncology, Vol. 25, No. 21, 20.07.2007, p. 3116-3123.

Research output: Contribution to journalArticle

Kong, FMS, Frey, KA, Quint, LE, Ten Haken, RK, Hayman, JA, Kessler, M, Chetty, IJ, Normolle, D, Eisbruch, A & Lawrence, TS 2007, 'A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non-small-cell lung cancer', Journal of Clinical Oncology, vol. 25, no. 21, pp. 3116-3123. https://doi.org/10.1200/JCO.2006.10.3747
Kong, Feng Ming Spring ; Frey, Kirk A. ; Quint, Leslie E. ; Ten Haken, Randall K. ; Hayman, James A. ; Kessler, Marc ; Chetty, Indrin J. ; Normolle, Daniel ; Eisbruch, Avraham ; Lawrence, Theodore S. / A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non-small-cell lung cancer. In: Journal of Clinical Oncology. 2007 ; Vol. 25, No. 21. pp. 3116-3123.
@article{6dc5a5ec849745bfaa5e0fbbe8a9c2e2,
title = "A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non-small-cell lung cancer",
abstract = "Purpose: To study whether changes of [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) during treatment correlate with post-treatment responses in tumor and normal lung in patients with non-small-cell lung cancer (NSCLC). Patients and Methods: Patients with stage I to III NSCLC requiring a definitive dose of fractionated radiation therapy (RT) were eligible. FDG-PET/computed tomography scans were acquired before, during, and after RT. Tumor and lung metabolic responses were assessed qualitatively by physicians and quantitatively by normalized peak FDG activity (the ratio of the maximum FDG activity divided by the mean of the aortic arch background). Results: The study reached the goal of recruiting 15 patients between February 2004 and August 2005. Of these, 11 patients had partial metabolic response, two patients had complete metabolic response, and two patients had stable disease at approximately 45 Gy during RT. The mean peak tumor FDG activity was 5.2 (95{\%} CI, 4.0 to 6.4), 2.5 (95{\%} CI, 2.0 to 3.0), and 1.7 (95{\%} CI, 1.3 to 2.0) on pre-, during, and post-RT scans, respectively. None of the patients had appreciable changes in the lung during RT. The peak FDG activity of the lung was 0.47 (95{\%} CI, 0.36 to 0.59), 0.52 (95{\%} CI, 0.40 to 0.64), and 1.29 (95{\%} CI, 0.82 to 1.76), on pre-, during-, and post-RT scans, respectively. The qualitative response during RT correlated with the overall response post-RT (P = .03); the peak tumor FDG activity during RT correlated with those 3 months post-RT (R2 = 0.7; P < .001). Conclusion: This pilot study suggests a significant correlation in tumor metabolic response and no association in lung FDG activity between during RT scans and 3 months post-RT scans in patients with NSCLC. Additional study with a large number of patients is needed to validate these findings.",
author = "Kong, {Feng Ming Spring} and Frey, {Kirk A.} and Quint, {Leslie E.} and {Ten Haken}, {Randall K.} and Hayman, {James A.} and Marc Kessler and Chetty, {Indrin J.} and Daniel Normolle and Avraham Eisbruch and Lawrence, {Theodore S.}",
year = "2007",
month = "7",
day = "20",
doi = "10.1200/JCO.2006.10.3747",
language = "English (US)",
volume = "25",
pages = "3116--3123",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "21",

}

TY - JOUR

T1 - A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non-small-cell lung cancer

AU - Kong, Feng Ming Spring

AU - Frey, Kirk A.

AU - Quint, Leslie E.

AU - Ten Haken, Randall K.

AU - Hayman, James A.

AU - Kessler, Marc

AU - Chetty, Indrin J.

AU - Normolle, Daniel

AU - Eisbruch, Avraham

AU - Lawrence, Theodore S.

PY - 2007/7/20

Y1 - 2007/7/20

N2 - Purpose: To study whether changes of [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) during treatment correlate with post-treatment responses in tumor and normal lung in patients with non-small-cell lung cancer (NSCLC). Patients and Methods: Patients with stage I to III NSCLC requiring a definitive dose of fractionated radiation therapy (RT) were eligible. FDG-PET/computed tomography scans were acquired before, during, and after RT. Tumor and lung metabolic responses were assessed qualitatively by physicians and quantitatively by normalized peak FDG activity (the ratio of the maximum FDG activity divided by the mean of the aortic arch background). Results: The study reached the goal of recruiting 15 patients between February 2004 and August 2005. Of these, 11 patients had partial metabolic response, two patients had complete metabolic response, and two patients had stable disease at approximately 45 Gy during RT. The mean peak tumor FDG activity was 5.2 (95% CI, 4.0 to 6.4), 2.5 (95% CI, 2.0 to 3.0), and 1.7 (95% CI, 1.3 to 2.0) on pre-, during, and post-RT scans, respectively. None of the patients had appreciable changes in the lung during RT. The peak FDG activity of the lung was 0.47 (95% CI, 0.36 to 0.59), 0.52 (95% CI, 0.40 to 0.64), and 1.29 (95% CI, 0.82 to 1.76), on pre-, during-, and post-RT scans, respectively. The qualitative response during RT correlated with the overall response post-RT (P = .03); the peak tumor FDG activity during RT correlated with those 3 months post-RT (R2 = 0.7; P < .001). Conclusion: This pilot study suggests a significant correlation in tumor metabolic response and no association in lung FDG activity between during RT scans and 3 months post-RT scans in patients with NSCLC. Additional study with a large number of patients is needed to validate these findings.

AB - Purpose: To study whether changes of [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) during treatment correlate with post-treatment responses in tumor and normal lung in patients with non-small-cell lung cancer (NSCLC). Patients and Methods: Patients with stage I to III NSCLC requiring a definitive dose of fractionated radiation therapy (RT) were eligible. FDG-PET/computed tomography scans were acquired before, during, and after RT. Tumor and lung metabolic responses were assessed qualitatively by physicians and quantitatively by normalized peak FDG activity (the ratio of the maximum FDG activity divided by the mean of the aortic arch background). Results: The study reached the goal of recruiting 15 patients between February 2004 and August 2005. Of these, 11 patients had partial metabolic response, two patients had complete metabolic response, and two patients had stable disease at approximately 45 Gy during RT. The mean peak tumor FDG activity was 5.2 (95% CI, 4.0 to 6.4), 2.5 (95% CI, 2.0 to 3.0), and 1.7 (95% CI, 1.3 to 2.0) on pre-, during, and post-RT scans, respectively. None of the patients had appreciable changes in the lung during RT. The peak FDG activity of the lung was 0.47 (95% CI, 0.36 to 0.59), 0.52 (95% CI, 0.40 to 0.64), and 1.29 (95% CI, 0.82 to 1.76), on pre-, during-, and post-RT scans, respectively. The qualitative response during RT correlated with the overall response post-RT (P = .03); the peak tumor FDG activity during RT correlated with those 3 months post-RT (R2 = 0.7; P < .001). Conclusion: This pilot study suggests a significant correlation in tumor metabolic response and no association in lung FDG activity between during RT scans and 3 months post-RT scans in patients with NSCLC. Additional study with a large number of patients is needed to validate these findings.

UR - http://www.scopus.com/inward/record.url?scp=34547681369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547681369&partnerID=8YFLogxK

U2 - 10.1200/JCO.2006.10.3747

DO - 10.1200/JCO.2006.10.3747

M3 - Article

C2 - 17634490

AN - SCOPUS:34547681369

VL - 25

SP - 3116

EP - 3123

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 21

ER -